PP

Prevail Partners

North America, Pennsylvania, United States, Philadelphia

Description

Prevail Partners is an investment fund focused on life sciences companies.

Investor Profile

Prevail Partners has backed more than 6 startups, with 1 new investments in the last 12 months alone. The firm has led 5 rounds, about 83% of its total and boasts 2 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series A, Series Unknown rounds (top funding stages).
  • Majority of deals are located in United States, United Kingdom, Canada.
  • Strong thematic focus on Health Care, Pharmaceutical, Biotechnology.
  • Led 1 rounds in the past year.

Stage Focus

  • Post Ipo Equity (33%)
  • Series A (33%)
  • Series Unknown (17%)
  • Seed (17%)

Country Focus

  • United States (50%)
  • United Kingdom (33%)
  • Canada (17%)

Industry Focus

  • Health Care
  • Pharmaceutical
  • Biotechnology
  • Medical Device
  • Medical
  • Oncology
  • Therapeutics
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Prevail Partners frequently co-invest with?

Tenmile
Oceania, Western Australia, Australia, Perth
Co-Investments: 1
Illini Angels
North America, Illinois, United States, Chicago
Co-Investments: 1
New Brunswick Innovation Foundation
North America, New Brunswick, Canada, Fredericton
Co-Investments: 1
Dream Ventures
North America, Nevada, United States, Las Vegas
Co-Investments: 1
Investissement Quebec
North America, Quebec, Canada, Quebec
Co-Investments: 1

What are some of recent deals done by Prevail Partners?

Coologics

Cleveland, Ohio, United States

Coologics operates as a clinical stage medical device company.

ManufacturingMedical Device
SeedApr 23, 2025
Amount Raised: $3,000,000
Triple Hair

Dieppe, New Brunswick, Canada

Triple Hair develops solutions for thinning hair and hair loss with dense regrowth.

Series UnknownJun 3, 2024
Amount Raised: $2,934,886
Stamford Pharmaceuticals

Houston, Texas, United States

Stamford Pharmaceuticals delivers biologicals, small molecule immune modulators, and chemotherapeutics to treat cancer patients.

Health CarePharmaceutical
Series AApr 10, 2024
HemoGenyx

London, England, United Kingdom

New treatment for blood diseases, such as leukemia and lymphoma.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquitySep 18, 2023
Amount Raised: $827,194
BriaCell Therapeutics

New York, New York, United States

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

BiotechnologyHealth CareMedicalOncologyPharmaceuticalTherapeutics
Post Ipo EquityMay 15, 2023
Amount Raised: $4,000,000
PolyPhotonix

Sedgefield, Durham, United Kingdom

PolyPhotonix is pioneering the early adoption of organic light.

Medical Device
Series AJan 10, 2022
Amount Raised: $10,000,000